Comparative Pharmacology
Head-to-head clinical analysis: PEMAZYRE versus REGORAFENIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMAZYRE versus REGORAFENIB.
PEMAZYRE vs REGORAFENIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
Regorafenib is a multikinase inhibitor that targets various angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, RAF). It inhibits tumor angiogenesis, growth, and metastasis.
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
160 mg orally once daily on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
Clinical Note
moderateRegorafenib + Digoxin
"Regorafenib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRegorafenib + Digitoxin
"Regorafenib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRegorafenib + Deslanoside
"Regorafenib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRegorafenib + Acetyldigitoxin
"Regorafenib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is 14–28 hours (mean approximately 20 hours), supporting twice-daily dosing with a 3-weeks-on/1-week-off schedule to allow washout and reduce toxicity accumulation.
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Primarily fecal (approximately 71% of the radiolabeled dose) with renal excretion accounting for 19% (mostly as metabolites). Unchanged regorafenib is minimal in urine.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor